Literature DB >> 27146001

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.

Dorothy I Jones1, Charles E McGee2, Christopher J Sample2, Gregory D Sempowski3, David J Pickup4, Herman F Staats5.   

Abstract

Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27146001      PMCID： PMC4933771          DOI： 10.1128/CVI.00216-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  31 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

2.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Stable dry powder formulation for nasal delivery of anthrax vaccine.

Authors:  Sheena H Wang; Shaun M Kirwan; Soman N Abraham; Herman F Staats; Anthony J Hickey
Journal:  J Pharm Sci       Date:  2011-09-08       Impact factor: 3.534

4.  Developmental and reproductive toxicity testing of vaccines.

Authors:  Paul Barrow
Journal:  J Pharmacol Toxicol Methods       Date:  2011-12-30       Impact factor: 1.950

5.  A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

Authors:  Ralf G Meyer; Cedrik M Britten; Ulrike Siepmann; Barbara Petzold; Tolga A Sagban; Hans A Lehr; Bernd Weigle; Marc Schmitz; Luis Mateo; Burkhard Schmidt; Helga Bernhard; Thilo Jakob; Rüdiger Hein; Gerold Schuler; Beatrice Schuler-Thurner; Stephan N Wagner; Ingo Drexler; Gerd Sutter; Nathaly Arndtz; Paul Chaplin; Jost Metz; Alexander Enk; Christoph Huber; Thomas Wölfel
Journal:  Cancer Immunol Immunother       Date:  2004-12-31       Impact factor: 6.968

6.  Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.

Authors:  Nicole L Garza; Josh M Hatkin; Virginia Livingston; Donald K Nichols; Paul J Chaplin; Ariane Volkmann; Diana Fisher; Aysegul Nalca
Journal:  Vaccine       Date:  2009-07-24       Impact factor: 4.169

Review 7.  Monitoring of human immunological responses to vaccinia virus.

Authors:  Richard Harrop; Matthew G Ryan; Hana Golding; Irina Redchenko; Miles W Carroll
Journal:  Methods Mol Biol       Date:  2004

8.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

9.  Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara.

Authors:  Christine Meisinger-Henschel; Michaela Schmidt; Susanne Lukassen; Burkhard Linke; Lutz Krause; Sebastian Konietzny; Alexander Goesmann; Paul Howley; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Gen Virol       Date:  2007-12       Impact factor: 3.891

10.  Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.

Authors:  Lindsay Crickard; Tahar Babas; Sidharth Seth; Peter Silvera; Lilia Koriazova; Shane Crotty
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240
View more
  2 in total

Review 1.  Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Authors:  A Volz; G Sutter
Journal:  Adv Virus Res       Date:  2016-08-01       Impact factor: 9.937

2.  40 Years without Smallpox.

Authors:  G A Shchelkunova; S N Shchelkunov
Journal:  Acta Naturae       Date:  2017 Oct-Dec       Impact factor: 1.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.